Cardiff Oncology/$CRDF
1D1W1MYTD1Y5YMAX
About Cardiff Oncology
Cardiff Oncology Inc is a clinical-stage biotechnology company advancing cancer treatments focused on PLK1 inhibition, a validated oncology target with practice-changing potential. Its main asset, onvansertib, is a specific, oral PLK1 inhibitor currently being evaluated in a Phase 2 trial for first-line treatment of RAS-mutated metastatic colorectal cancer (mCRC), addressing a large, underserved patient population with high unmet need. Onvansertib is also under investigation in other PLK1-driven cancers through ongoing investigator-initiated trials and has shown robust single agent clinical activity in hard-to-treat tumors. By targeting tumor vulnerabilities, to overcome treatment resistance and deliver improved clinical outcomes for patients.
- Ticker
- $CRDF
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 31
- Headquarters
- San Diego, United States
- Website
- www.cardiffoncology.com
Cardiff Oncology Metrics
BasicAdvanced
$77M
-
-$0.59
1.44
-
Price and volume
Market cap
$77M
Beta
1.44
52-week high
$3.31
52-week low
$0.76
Average daily volume
904K
Financial strength
Current ratio
3.296
Quick ratio
3.215
Total debt to equity
1.722
Profitability
EBITDA (TTM)
-41.915
Gross margin (TTM)
-6,854.53%
Net profit margin (TTM)
-7,884.06%
Operating margin (TTM)
-8,320.08%
Revenue per employee (TTM)
$20,000
Management effectiveness
Return on assets (TTM)
-46.73%
Return on equity (TTM)
-94.08%
Valuation
Price to revenue (TTM)
131.55
Price to book
2.55
Price to tangible book (TTM)
2.55
Price to free cash flow (TTM)
-1.633
Free cash flow yield (TTM)
-61.23%
Free cash flow per share (TTM)
-0.604
Growth
Revenue change (TTM)
-6.79%
Earnings per share change (TTM)
-32.18%
3-year revenue growth (CAGR)
7.23%
10-year revenue growth (CAGR)
3.49%
3-year earnings per share growth (CAGR)
-12.91%
10-year earnings per share growth (CAGR)
-39.26%
What the Analysts think about Cardiff Oncology
Analyst ratings (Buy, Hold, Sell) for Cardiff Oncology stock.
Cardiff Oncology Financial Performance
Revenues and expenses
Cardiff Oncology Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.